Humedix Co Ltd Asset Resilience Ratio
Humedix Co Ltd asset resilience ratio. Humedix Co Ltd (200670) has an Asset Resilience Ratio of 18.56% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 200670 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Humedix Co Ltd (2015–2025)
Asset resilience ratio of Humedix Co Ltd from 2015 to 2025. This chart shows how Humedix Co Ltd's Asset Resilience Ratio has changed over time. Read 200670 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Humedix Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 200670 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩62.11 Billion | 18.56% |
| Total Liquid Assets | ₩62.11 Billion | 18.56% |
Asset Resilience Insights
- Good Liquidity Position: Humedix Co Ltd maintains a healthy 18.56% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Humedix Co Ltd Industry Peers by Asset Resilience Ratio
Compare Humedix Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Humedix Co Ltd Asset Resilience Ratio by Year (2015–2025)
Humedix Co Ltd asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Humedix Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.27% | ₩85.03 Billion ≈ $57.62 Million |
₩323.64 Billion ≈ $219.33 Million |
-5.29pp |
| 2024-12-31 | 31.56% | ₩78.82 Billion ≈ $53.42 Million |
₩249.75 Billion ≈ $169.25 Million |
+4.28pp |
| 2023-12-31 | 27.28% | ₩60.00 Billion ≈ $40.66 Million |
₩219.98 Billion ≈ $149.08 Million |
-7.95pp |
| 2022-12-31 | 35.23% | ₩80.01 Billion ≈ $54.22 Million |
₩227.14 Billion ≈ $153.93 Million |
+10.05pp |
| 2021-12-31 | 25.18% | ₩54.35 Billion ≈ $36.83 Million |
₩215.86 Billion ≈ $146.29 Million |
+0.33pp |
| 2020-12-31 | 24.85% | ₩43.66 Billion ≈ $29.59 Million |
₩175.65 Billion ≈ $119.03 Million |
+10.84pp |
| 2019-12-31 | 14.02% | ₩19.41 Billion ≈ $13.15 Million |
₩138.42 Billion ≈ $93.81 Million |
-9.32pp |
| 2018-12-31 | 23.34% | ₩29.94 Billion ≈ $20.29 Million |
₩128.28 Billion ≈ $86.93 Million |
-6.00pp |
| 2017-12-31 | 29.34% | ₩38.06 Billion ≈ $25.79 Million |
₩129.74 Billion ≈ $87.92 Million |
-16.31pp |
| 2016-12-31 | 45.64% | ₩59.86 Billion ≈ $40.57 Million |
₩131.16 Billion ≈ $88.88 Million |
+45.42pp |
| 2015-12-31 | 0.22% | ₩252.88 Million ≈ $171.37K |
₩115.90 Billion ≈ $78.54 Million |
-- |
About Humedix Co Ltd
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more